Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Actelion Pharmaceuticals Ltd.

    Client Virtual Booth

    ACTELION PHARMACEUTICALS LTD

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Actelion Pharmaceuticals Ltd
    Switzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Gewerbestrasse 16 CH-4123 Allschwil
    Telephone
    Telephone
    +41 61 565 65 65
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.actelion.com
    Linkedin
    Linkedin
    https://www.linkedin.com/company/actelion
    Twitter
    Twitter
    https://twitter.com/actelion_com?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Juvisé Pharmaceuticals Acquires Multiple Sclerosis Drug PONVORY® (ex-US/Canada) and Opens its Capital to Bpifrance and Pemberton

    Details:

    Through the acquisition, Juvise Pharmaceuticals will leverage its expertise to commercialize and develop Ponvory(ponesimod), a first-line treatment option in active forms of relapsing multiple sclerosis, outside of the United States and Canada, with a focus on Europe.


    Lead Product(s): Ponesimod

    Therapeutic Area: Neurology Product Name: Ponvory

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Juvise Pharmaceuticals

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition March 26, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multi...

    Details:

    Through the acquisition, Vanda expands its commercial portfolio by including Ponvory (ponesimod), a daily oral selective sphingosine-1-phosphate receptor 1 (S1P1R) modulator, indicated to treat adults with relapsing forms of multiple sclerosis.


    Lead Product(s): Ponesimod

    Therapeutic Area: Neurology Product Name: Ponvory

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Vanda Pharmaceuticals

    Deal Size: $100.0 million Upfront Cash: Undisclosed

    Deal Type: Acquisition December 07, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Beyond Batten Disease Foundation Announces Agreement with Actelion Pharmaceuticals Ltd to Provide Drug Product for BBDF-101

    Details:

    Janssen will provide drug supply for the clinical trials and Extended Access Program, and right of reference to data within the Zavesca New Drug Application (NDA) to support the development of BBDF-101.


    Lead Product(s): Miglustat,Trehalose API

    Therapeutic Area: Genetic Disease Product Name: BBDF 101

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Beyond Batten Disease Foundation

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration March 02, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    TRITON Phase 3b Study Results Presented at the European Society of Cardiology Congress

    Details:

    While the primary endpoint was not met, exploratory analysis suggests a signal of reduced risk of disease progression of initial triple oral combination therapy vs initial double oral therapy for Pulmonary Arterial Hypertension (PAH) patients .


    Lead Product(s): Selexipag,Macitentan,Tadalafil

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: Uptravi

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 29, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search